OBJECTIVE: Myocardial inflammation during myocardial infarction (MI) could be inhibited by regulating arachidonic acid (AA) metabolism. Recent studies demonstrated that Sini Decoction (SND) was identified to be an effective prescription for treating heart failure (HF) caused by MI. But the anti-inflammatory mechanism of SND remained unclear. The work was designed to investigate the anti-inflammatory mechanism of SND through the AA metabolism pathway in vitro and in vivo experiments. METHODS: An inflammatory injury model of H9c2 cells was established by lipopolysaccharide (LPS)-stimulated macrophage-conditioned medium (CM). The MI model was built by the ligation of left anterior descending (LAD) branch of coronary artery in rat. Meanwhile, the rats were divided into five groups: sham group, MI group, MI + Celecoxib group, MI + low-dose SND group (SND-L) and MI + high-dose SND group (SND-H). Cardiac function, histopathological changes and serum cytokines were examined four weeks later. Western blot analysis was conducted to verify the key enzymes levels in the AA metabolic pathway, including phospholipase A2 (PLA2), cyclooxygenases (COXs) and lipoxygenases (LOXs). RESULTS: These in vivo results demonstrated that SND could improve the cardiac function and pathological changes of rats with MI, and regulate the key inflammatory molecules in the AA metabolism pathway, including sPLA2, COX-1, COX-2, 5-LOX and 15-LOX. In vitro, SND could decrease the release of pro-inflammatory cytokines including TNF-α and IL-6 and inhibit cell apoptosis in CM-induced H9c2 cells. Moreover, SND could protect H9c2 cells from the damage of CM by regulating nuclear factor kappa-B (NF-κB) signal pathway and the expression of COX-2. CONCLUSION SND may be a drug candidate for anti-inflammatory treatment during MI by regulating the multiple targets in the AA metabolism pathway.

Gastric cancer is a malignant tumor of the digestive system with strong invasiveness and a high metastasis rate.Its morbidity and mortality rank among the top five in the world and the prognosis is closely related to the disease stage.Multidisciplinary comprehensive treatment based on systemic antitumor drugs is generally adopted in patients with advanced or metastatic gastric can-cer,but the prognosis is typically poor.With the in-depth research on the tumor microenvironment,the development of multi-omics technology,and the application of immunotherapy and neoadjuvant chemoradiotherapy,the therapeutic effect of advanced gastric can-cer has been initially improved,and immunotherapy has become the most potential of the treatment strategies.Many studies have found that Helicobacter pylori(Hp)infection status is closely related to the efficacy of immunotherapy for gastric cancer,especially im-mune checkpoint inhibitors(ICIs),but there is not clear whether it has advantages or disadvantages.This article reviews the current research on the efficacy of Hp on ICIs in advanced gastric cancer to provide ideas for further research on the interaction between Hp in-fection and tumor immunotherapy.

Objective Based on a clinical cohort study of repeated ketamine infusions for treatment-resistant depression(TRD),this study aimed to examine differences in brain-derived neurotrophic factor(BDNF)methylation among patients with varying therapeutic responses and explore its potential role in predicting treatment efficacy.Methods A retrospective analysis was conducted on peripheral plasma BDNF levels in 83 patients with TRD before and after a 2-week course of ketamine treatment(6 injections total).The Montgomery-Asberg depression rating scale(MADRS)was used to assess treatment efficacy.BDNF methylation levels were compared between responder group and non-responder group.The effect of methylation of the target CpG site on transcriptional activity was verified by using the dual luciferase reporter gene system.Results In patients with TRD who completed six repeated ketamine infusions,the responder group showed significant improvements compared to baseline levels in both MADRS scores(25.20±7.54 vs.8.10±5.32,P<0.01)and plasma BDNF concentrations[8.74(5.26,13.46)ng/mL vs.16.59(7.41,24.46)ng/mL,P<0.01].At baseline,35 CpG sites within the BDNF gene displayed significant methylation differences between response groups(P<0.05).Two CpG sites(rs1240718851 and cg06260077)located in the BDNF promoter region demonstrated a hypermethylation-low expression correlation,and dual-luciferase reporter assays confirmed that one of these sites functionally modulates BDNF expression.Conclusions The plasma BDNF concentration in TRD patients increases with the remission of depressive symptoms.The regulation of BDNF gene expression by methylation can predict the antidepressant efficacy of repeated intravenous ketamine.

Objective To delineate the current research landscape,emerging hotspots,and frontiers re-garding the relationship between the oral microbiome and digestive system diseases.Methods We retrieved publications from the Web of Science Core Collection database using topic-specific queries on"oral microbi-ome"and"digestive diseases."Bibliometric analysis was performed using VOSviewer,CiteSpace,and the"bibliometrix"package in R for data mining and visualization.Results A total of 1228 eligible articles were included.Analysis revealed that research on the correlation between oral microbiota and digestive system diseases will remain a global hotspot.Academic institutions dominated the publications,with centralized institutional distribution and team-based collaboration,though overall collaboration networks remained fragmented.Geo-graphically,the United States emerged as the leading contributor,followed by China and the United Kingdom.While China-U.S.collaborations were prominent,China's engagement with other regions remained limited.Current research hotspots focus on the interplay between oral microbiota and gut microbiota,inflam-matory bowel disease(IBD),and digestive system tumors.Conclusions Research in this field demonstrates high activity and diversity.Studies on the associations of oral microbiota with gut microbiota,IBD,and diges-tive system tumors(particularly esophageal,gastric,pancreatic,and colorectal cancers)remain prominent.Future studies should prioritize elucidating underlying mechanisms and innovating in biomarker discovery and application.However,insufficient collaboration and resource-sharing among institutions currently hinder pro-gress in this field.

OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of toripalimab （Tor） combined with chemotherapy （CT） in the treatment of locally advanced or metastatic non-small cell lung cancer （NSCLC）. METHODS PubMed， the Cochrane Library， Embase， Web of Science， CBM， CNKI， Wanfang Data， and Health Technology Assessment （HTA） related websites were searched to collect the HTA reports， systematic reviews/meta-analyses and pharmacoeconomic studies of Tor+CT in the treatment of locally advanced or metastatic NSCLC from database/website inception to March 31， 2025. After data extraction and quality evaluation， the results of the included studies were analyzed descriptively. RESULTS A total of eleven studies were included， involving five systematic reviews/meta-analyses， and six pharmacoeconomic studies. Among the five systematic reviews/ meta-analyses， two were of high quality， while there was one each of moderate， low， and very low quality. All six pharmacoeconomic studies were of good quality. In terms of efficacy， compared with CT， Tor+CT significantly improved patients’ progression-free survival （PFS） and overall survival （P＜0.05）. In addition， compared with ipilimumab+CT， durvalumab， durvalumab+tremelimumab and sugemalimab+CT， Tor+CT could also improve the PFS （P＜0.05）. In terms of safety， there was no significant difference in the incidence of grade≥3 adverse events between patients receiving Tor+CT and CT （P＞0.05）； while Tor+CT had a lower incidence of grade≥3 adverse E-mail： events， compared with camrelizumab+CT， pembrolizumab+ 3233255290@qq.com ipilimumab， nivolumab+CT and atezolizumab+CT （P＜0.05）.In terms of cost-effectiveness， Tor+CT treatment had certain cost-effectiveness advantages， compared with CT. CONCLUSIONS Compared with CT， other programmed death-1/programmed death-ligand 1 inhibitors alone， or their combination with CT， Tor+CT for the treatment of locally advanced or metastatic NSCLC has good efficacy， safety and cost-effectiveness.

Objective To investigate the detection conditions,risk factors and preventive measures of colorectal polyps in health examination population undergoing painless colonoscopy.Methods A total of 2 680 people who underwent painless colonoscopy at the Health Management Center of the First Affiliated Hospital of Naval Medical University from January to December 2023 were enrolled in this retrospective study.They were assigned into polyp group and non-polyp group according the examination results.The general information of the two groups was collected to explore the risk factors of colorectal polyps,so as to provide reference for the prevention strategy of colorectal polyps.Results The colorectal polyps were detected in 1 223 people(45.63%),including 633 cases(51.76%)of adenomatous polyps,587 cases(48.00%)of non-adenomatous polyps,and 3 cases(0.25%)of colorectal cancer.Logistic regression analysis indicated that male,smoking history,alcohol drinking history,age 40-59 years old,hyperlipidemia,and CRP>10 mg/L were risk factors of colorectal polyps(P<0.05).Conclusion There is a high detection rate of colorectal polyps in physical examination population.Men,aged 40-59 years old,hyperlipidemia,smoking history,alcohol drinking history,and CRP>10 mg/L are high risk factors of colorectal polyps,which should be paid more attention for the prevention and monitoring of colorectal polyps.

Objective To delineate the current research landscape,emerging hotspots,and frontiers re-garding the relationship between the oral microbiome and digestive system diseases.Methods We retrieved publications from the Web of Science Core Collection database using topic-specific queries on"oral microbi-ome"and"digestive diseases."Bibliometric analysis was performed using VOSviewer,CiteSpace,and the"bibliometrix"package in R for data mining and visualization.Results A total of 1228 eligible articles were included.Analysis revealed that research on the correlation between oral microbiota and digestive system diseases will remain a global hotspot.Academic institutions dominated the publications,with centralized institutional distribution and team-based collaboration,though overall collaboration networks remained fragmented.Geo-graphically,the United States emerged as the leading contributor,followed by China and the United Kingdom.While China-U.S.collaborations were prominent,China's engagement with other regions remained limited.Current research hotspots focus on the interplay between oral microbiota and gut microbiota,inflam-matory bowel disease(IBD),and digestive system tumors.Conclusions Research in this field demonstrates high activity and diversity.Studies on the associations of oral microbiota with gut microbiota,IBD,and diges-tive system tumors(particularly esophageal,gastric,pancreatic,and colorectal cancers)remain prominent.Future studies should prioritize elucidating underlying mechanisms and innovating in biomarker discovery and application.However,insufficient collaboration and resource-sharing among institutions currently hinder pro-gress in this field.

As a physical treatment technique, modified electro-convulsive therapy (MECT) is used to treat mental and certain neurological disorders by causing seizures with short, suitable electrical currents applied to the brain while the patient is under general anesthesia and muscle relaxants. MECT is recognized for its therapeutic efficacy and clinical safety, rendering it one of the most prevalent interventions in psychiatric care. To enhance clinical outcomes and minimize adverse effects, this consensus document delineates the indications, therapeutic parameters, therapeutic procedures, potential adverse effects, and associated management strategies for MECT. These guidelines are informed by the latest clinical research and expert consensus, integrating evidence-based medicine methodologies. The objective is to furnish clinicians with precise operational guidelines and to advance the standardization of MECT practices in clinical settings.

Objective To investigate the association of ondansetron use with short-term mortality risk and long-term mortality risk in patients with cerebrovascular disease.Methods Clinical data of patients with cerebrovascular disease admitted to the intensive care unit(ICU)between 2008 and 2022 from the MIMIC-Ⅳ database were retrospectively collected.All enrolled subjects were divided into an ondansetron group and a non-ondansetron group according to whether they had used ondansetron during their hospitalization.The differences in clinical indicators between the two groups were equalized using a 1∶1 propensity score matching(PSM)method.Kaplan-Meier survival analyses were employed to compare the differences in survival rates between the two groups at ICU,hospital,30-and 90-day,respectively.Cox proportional-hazards regression models were employed to analyze the associations between ondansetron use and ICU,hospital,and 30-and 90-day all-cause mortality in critically ill patients with cerebrovascular disease.Results The study included 9,198 patients with cerebrovascular disease,including 3,514 in the ondansetron group and 5,684 in the non-ondansetron group.Pre-matched baseline data showed that the overall ICU,hospital,and 30-and 90-day mortality rates in the ondansetron group were 7.0％,12.4％,15.9％,and 21.3％respectively,while those in the non-ondansetron group were 11.0％,17.2％,22.3％and 27.9％respectively.After 1∶1 PSM equalization of baseline data,a total of 3,239 pairs were successfully matched.Based on the matched data,Kaplan-Meier survival analyses showed higher survival rates of ICU(P＜0.001),hospital(P＜0.001),30 d(P＜0.001),and 90 d(P＜0.001)in the ondansetron group compared to the non-ondansetron group.In Cox proportional-hazards analysis,after adjustment for potential confounders,the hazard ratios(HR)in the ondansetron group relative to the non-ondansetron group were 0.60[95％CI(0.51,0.71),P＜0.001]for ICU mortality,0.73[95％CI(0.64,0.83),P＜0.001]for hospital mortality,0.76[95％CI(0.67,0.85),P＜0.001]for 30 d mortality,and 0.81[95％CI(0.73,0.89),P＜0.001]risk ratio for 90 d mortality.Conclusion The use of ondansetron may significantly decrease the ICU,hospital,30 d and 90 d risk of mortality in patients with severe cerebrovascular disease.